Stock in Focus: Bristol-Myers Squibb (NYSE:BMY)

[BUSINESS WIRE] Bristol-Myers Squibb (NYSE:BMY) announced that ten abstracts have been accepted for presentation at IDWeek 2014™, which is taking place in Philadelphia, PA, October 8-12, 2014. The breadth of data being presented highlights Bristol-Myers Squibb’s commitment to discover, develop and deliver innovative medicines that help patients prevail over chronic viral diseases.Stock PerformanceTaking a look at the company’s recent performance, Bristol-Myers Squibb (BMY) reported Second quarter earnings for fiscal 2014 on July 24^th. The company reported actual earnings per share of $0.48 against the consensus Street estimate of $0.44. This represents year over year growth of 8.33%. Bristol-Myers Squibb posted revenue of $3.89 billion against estimates of $3.85 billion.Bristol-Myers Squibb (BMY) is currently valued at $81.02 billion and closed the last trading session at $48.92. The stock has a 50-day moving average of $50.75 and a 200-day moving average of $49.85.

Is this a Buying Opportunity?There are currently sixteen analysts that we track that cover the stock. Of those sixteen, six have a Buy rating, nine have a hold rating and one has a Sell rating. On a consensus basis this yields a score of 2.31 and a Hold. The combined price objective of these covering analysts is $52.35, which represents a 2.96% upside difference to the last closing price.The most recent analyst activity consisted of Guggenheiminitiating coverage with Neutral stance on the company. Guggenheim has a price target of $57.00 which represents an upside of 13.52% from the last closing price. On the date of the report, the stock closed at $50.21.Another research firm weighing in recently was Zacks who reiterated their rating on the stock. On July 23^rd Zacks boosted their price target on the stock from $54.00, or a 5.28% upside to the current price. On the day of the report, BMY shares closed at $51.29.Company ProfileBristol-Myers Squibb (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular.